Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Trial Timeline
Jan 10, 2022 → May 8, 2025
NCT ID
NCT05092360About Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + Gemcitabine is a phase 3 stage product being developed by Merck for Platinum-resistant Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05092360. Target conditions include Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Platinum-resistant Ovarian Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05092360 | Phase 3 | Terminated |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer